Repositioning Candidate Details
Candidate ID: | R0730 |
Source ID: | DB05194 |
Source Type: | investigational |
Compound Type: | small molecule |
Compound Name: | KB002 |
Synonyms: | -- |
Molecular Formula: | -- |
SMILES: | -- |
DrugBank Description: | KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis. |
CAS Number: | -- |
Molecular Weight: | |
DrugBank Indication: | Investigated for use/treatment in rheumatoid arthritis. |
DrugBank Pharmacology: | -- |
DrugBank MoA: | KB002 is an engineered human monoclonal antibody. The drug targets and neutralizes the activity of granulocyte macrophage colony-stimulating factor, (GM-CSF), a pro-inflammatory cytokine/growth factor that stimulates the survival, proliferation, differentiation and function of several types of white blood cells, including the monocytes/macrophages that play a key role in the tissue damage associated with many autoimmune diseases. |
Targets: | Granulocyte-macrophage colony-stimulating factor receptor subunit alpha; Granulocyte-macrophage colony-stimulating factor; GM-CSF receptor alpha subunit |
Inclusion Criteria: | Therapeutic strategy associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Diseases ID | DO ID | Disease Name | Definition | Class | |
---|---|---|---|---|---|
I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |